keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation anti-TNF

keyword
https://www.readbyqxmd.com/read/28917981/intranasal-insulin-treatment-alleviates-methamphetamine-induced-anxiety-like-behavior-and-neuroinflammation
#1
Elmira Beirami, Shahrbanoo Oryan, Seyedeh Masoumeh Seyedhoseini Tamijani, Abolhassan Ahmadiani, Leila Dargahi
Insulin, as a peptide hormone, has recently gained attention for its pro-cognitive, anti-inflammatory and neuroprotective effects in the central nervous system (CNS). Most studies have indicated anxiogenic and neuroinflammatory effects of methamphetamine (MA) and other psychostimulants, even after periods of abstinence. The present study aimed to examine whether intranasal (IN) insulin treatment with high CNS bioavailability and minimal systemic side effects, can reverse the anxiety-like behavior and neuroinflammation induced by repeated MA administration...
September 13, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28901727/retention-rates-of-adalimumab-etanercept-and-infliximab-as-first-line-biotherapy-agent-for-rheumatoid-arthritis-patients-in-daily-practice-auvergne-experience
#2
Martin Soubrier, Bruno Pereira, Thomas Frayssac, Angelique Fan, Marion Couderc, Sandrine Malochet-Guinamand, Sylvain Mathieu, Zuzana Tatar, Anne Tournadre, Jean-Jacques Dubost
OBJECTIVE: To compare, in real-life conditions, the retention rates of anti-tumor necrosis factor (anti-TNF) treatment (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) initiated as first-line biotherapy for rheumatoid arthritis (RA) and to evaluate, in case of failure, the switch to another anti-TNF or a non-anti-TNF biological. METHODS: Monocentric retrospective cohort including all patients with RA starting a first anti-TNF between 2001 and 2015. RESULTS: Among the 346 patients analyzed, 201 received ETN, 82 ADA and 63 IFX...
September 13, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28861167/can-rheumatoid-arthritis-ever-cease-to-exist-a-review-of-various-therapeutic-modalities-to-maintain-drug-free-remission
#3
Di Liu, Na Yuan, Guimei Yu, Ge Song, Yan Chen
Therapies for rheumatoid arthritis (RA) were mostly aimed at reducing the pain, stiffness and further progression of joint destruction. However, with the advent of biologic agents that act against specific inflammatory cytokines contributing to RA pathogenesis (treat-to-target strategy), the degree of remission achieved has been remarkably impressive. In particular, inhibition of tumor necrosis factor α (TNFα), interleukins-1 and -6 and receptor-activator of nuclear kappa B ligand by neutralizing antibodies in early diagnosed RA patients has resulted in lowering of disease activity to levels that enable them to function as in the pre-disease stage...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28858070/anti-tnf-%C3%AE-use-during-the-third-trimester-of-pregnancy-in-women-with-moderate-severe-inflammatory-bowel-disease-and-the-risk-of-preterm-birth-and-low-birth-weight
#4
Heidi Kammerlander, Jan Nielsen, Torben Knudsen, Jens Kjeldsen, Sonia Friedman, Bente Mertz Nørgård
BACKGROUND: Little knowledge exists about the association between anti-tumor necrosis factor-alpha (anti-TNF-α) therapy for inflammatory bowel disease during late pregnancy and adverse birth outcomes. We aimed to examine whether treatment with anti-TNF-α during the third trimester affected preterm birth and low birth weight (LBW), compared with women who discontinued anti-TNF-α therapy before the third trimester. METHODS: We identified a nationwide cohort of 219 women treated with anti-TNF-α during the pregnancy period and reviewed the medical records to extract clinical details...
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28834393/drug-free-long-term-remission-in-severe-behcet-s-disease-following-withdrawal-of-successful-anti-tnf-treatment
#5
Petros P Sfikakis, Aikaterini Arida, Stylianos Panopoulos, Kalliopi Fragiadaki, George Pentazos, Katerina Laskari, Maria Tektonidou, Nikos Markomichelakis
OBJECTIVE: To test the hypothesis that remission of Behcet's disease (BD) with severe vital organ involvement is maintained after withdrawal of successful anti-TNF treatment. METHODS: This single-center, retrospective, longitudinal outcome study focused on consecutive patients, refractory to conventional immunosuppressants, who responded to add-on anti-TNF long-term treatment, which was subsequently discontinued. Endpoint was patients' proportion remaining in complete remission for at least 3 years after anti-TNF withdrawal...
August 22, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28831751/discontinuation-of-biologic-therapy-in-rheumatoid-arthritis-analysis-from-the-corrona-ra-registry
#6
Vibeke Strand, Paul Miller, Setareh A Williams, Katherine Saunders, Shannon Grant, Joel Kremer
INTRODUCTION: Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons for discontinuation. METHODS: Inclusion criteria were: Corrona-registered adults (≥18 years) with RA (2002-2011); age of RA onset: ≥16 years; ≥6 months' follow-up after initiation of first/subsequent bDMARD...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28826571/indicators-of-suboptimal-tumor-necrosis-factor-antagonist-therapy-in-inflammatory-bowel-disease
#7
James O Lindsay, Alessandro Armuzzi, Javier P Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C Nguyen, Michael Smyth, Haridarshan Patel
BACKGROUND: Inflammatory bowel disease (IBD) is refractory to treatment in one-half of patients. AIMS: To evaluate the occurrence of suboptimal therapy among patients with IBD treated with tumor necrosis factor antagonists (anti-TNFs). METHODS: A multinational chart review in Europe and Canada was conducted among IBD patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who initiated anti-TNF therapy between 2009 and 2013...
August 1, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28818362/two-year-follow-up-of-crohn-s-patients-substituted-to-certolizumab-anti-tnfa-therapy-savant-2
#8
Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J Steven Alexander
The effectiveness of ant-TNF 'biologic' therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first 'SAVANT' study was to our knowledge the first study report one- year outcomes in patients (n=60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1...
August 9, 2017: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/28800384/exploring-conditions-for-redistribution-of-anti-tnfs-to-reduce-spillage-a-study-on-the-quality-of-anti-tnf-home-storage
#9
Marin J de Jong, Marieke J Pierik, Andy Peters, Mark Roemers, Veronique Hilhorst, Astrid van Tubergen
BACKGROUND AND AIM: Biologicals are potent drugs for immune mediated inflammatory diseases (IMIDs). After discontinuation or switch of therapy, many patients have unused biological injectors left. We aimed to evaluate potential redistribution of unused injectors to prevent spillage of these costly drugs by assessing 1) the quality of transport and home storage through the proportion of injectors stored within the recommended temperature range (2°C-8°C) and 2) acceptance of redistribution by patients...
August 11, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28764705/drug-survival-of-second-biological-dmard-therapy-in-patients-with-rheumatoid-arthritis-a-retrospective-non-interventional-cohort-analysis
#10
Thomas Wilke, Sabrina Mueller, Sze Chim Lee, Istvan Majer, Marieke Heisen
BACKGROUND: Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However, little is known about treatment persistence of the second-line bDMARD and it is specifically unknown whether the mode of action of such a treatment is associated with different persistence rates. We aimed to assess discontinuation-, re-initiation- or continuation-rates of a 2nd bDMARD therapy as well as switching-rates to a third biological DMARD (3rd bDMARD) therapy in RA patients...
August 2, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28752637/anti-tnf-treatment-in-crohn-s-disease-and-risk-of-bowel-resection-a-population-based-cohort-study
#11
M Eberhardson, J K Söderling, M Neovius, T Cars, P Myrelid, J F Ludvigsson, J Askling, A Ekbom, O Olén
BACKGROUND: TNF inhibitors (TNFi) have been shown to reduce the need for surgery in Crohn's disease, but few studies have examined their effect beyond the first year of treatment. AIM: To conduct a register-based observational cohort study in Sweden 2006-2014 to investigate the risk of bowel resection in bowel surgery naïve TNFi-treated Crohn's disease patients and whether patients on TNFi ≥12 months are less likely to undergo bowel resection than patients discontinuing treatment before 12 months...
September 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28743358/higher-body-mass-index-and-anti-drug-antibodies-predict-the-discontinuation-of-anti-tnf-agents-in-korean-patients-with-axial-spondyloarthritis
#12
Jiwon Hwang, Hye-Mi Kim, Hyemin Jeong, Jaejoon Lee, Joong Kyong Ahn, Eun-Mi Koh, Eun-Suk Kang, Hoon-Suk Cha
OBJECTIVE: The development of anti-drug antibodies against tumor necrosis factor inhibitors is a likely explanation for the failure of TNF-inhibitors in patients with spondyloarthritis. Our study determined the existence and clinical implications of ADAbs in axial spondyloarthritis patients. METHODS: According to the Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis, patients treated with adalimumab or infliximab were recruited consecutively...
July 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28717941/the-comparative-safety-of-tnf-inhibitors-in-ankylosing-spondylitis-a-meta-analysis-update-of-14-randomized-controlled-trials
#13
Li-Qiong Hou, Ga-Xue Jiang, Yan-Fei Chen, Xi-Mei Yang, Lei Meng, Miao Xue, Xiao-Guang Liu, Xi-Chao Chen, Xiao Li
TNF inhibitors have been used in ankylosing spondylitis (AS). The efficacy of TNF inhibitors was already evaluated by meta-analysis of randomized controlled trials (RCTs). However, the safety of TNF inhibitors is still unclear. Therefore, we aimed to evaluate and update the safety data from RCTs of TNF inhibitors in patients treated for AS. A systematic literature search was conducted from 1990 through May 31, 2016. All studies included were randomized, double-blind, controlled trials of patients with ankylosing spondylitis that evaluated adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab treatment...
July 17, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28644565/long-term-risk-of-infection-in-patients-with-crohn-s-disease-on-anti-tnf-treatment-a-prospective-single-center-cohort-study-in-china
#14
Yue Li, Hui Jun Shu, Hong Lu, Hong Yang, Ji Li, Bei Tan, Jia Ming Qian
OBJECTIVE: The aim of this study was to explore the long-term risk of infection in patients with Crohn's disease (CD) on infliximab (IFX) therapy. METHODS: All CD patients treated with IFX were recruited from January 2008 to December 2015. Their characteristics and infectious events during IFX therapy were prospectively collected, and the risk of infection was evaluated using Cox regression. RESULTS: Seventy CD patients receiving IFX were consecutively recruited...
July 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28643285/skin-manifestations-of-inflammatory-bowel-disease
#15
REVIEW
Thomas Greuter, Alexander Navarini, Stephan R Vavricka
Inflammatory bowel disease (IBD) with its two main subtypes Crohn's disease and ulcerative colitis is not restricted to the gastrointestinal tract. Indeed, so-called extraintestinal manifestations (EIMs) are frequent and considerably affect morbidity and mortality. The prevalence of EIMs ranges from 6 to 47%. In up to one quarter of the patients, EIMs can present even before an IBD diagnosis is established. The pathophysiology of EIMs remains elusive, although data from clinical trials demonstrating anti-tumor necrosis factor (TNF) efficacy suggest a common pathogenic link between intestinal and extraintestinal disease activity...
June 23, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28597181/clinical-signs-pathophysiology-and-management-of-cutaneous-side-effects-of-anti-tumor-necrosis-factor-agents
#16
REVIEW
Siegfried Segaert, Caroline Hermans
Approximately one in four patients treated with anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab, and golimumab) develops cutaneous adverse events, typically months to years after the initiation of treatment, with xerosis cutis, eczema (often psoriasiform), psoriasis, palmoplantar pustulosis, cutaneous infections, alopecia, and skin cancer being the most frequently encountered. The typical skin lesion of anti-tumor necrosis factor (TNF)-treated patients is orange-red psoriasiform eczema affecting the flexures, genitalia, scalp, or face, with high susceptibility to bacterial superinfection with Staphylococcus aureus...
June 8, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28597133/real-life-10-year-retention-rate-of-first-line-anti-tnf-drugs-for-inflammatory-arthritides-in-adult-and-juvenile-onset-populations-similarities-and-differences
#17
Ennio Giulio Favalli, Irene Pontikaki, Andrea Becciolini, Martina Biggioggero, Nicola Ughi, Micol Romano, Chiara Crotti, Maurizio Gattinara, Valeria Gerloni, Antonio Marchesoni, Pier Luigi Meroni
The aim of this study is to retrospectively analyze 10-year drug survival of first-line TNF inhibitor (TNFi) in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) patients, comparing withdrawal rates and discontinuation pattern between adult- and juvenile-onset populations. RA, AS, PsA, and JIA patients treated with infliximab, etanercept, or adalimumab as first TNFi between 1999 and 2015 were extracted from a local registry. Drug survival up to 10-year follow-up was evaluated by the Kaplan-Meier method and compared according to age (adult vs juvenile onset), TNFi agent, and discontinuation reason by a stratified log-rank test...
August 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28593685/one-year-effectiveness-and-safety-of-vedolizumab-therapy-for-inflammatory-bowel-disease-a-prospective-multicentre-cohort-study
#18
A Amiot, M Serrero, L Peyrin-Biroulet, J Filippi, B Pariente, X Roblin, A Buisson, C Stefanescu, C Trang-Poisson, R Altwegg, P Marteau, T Vaysse, A Bourrier, S Nancey, D Laharie, M Allez, G Savoye, J Moreau, L Vuitton, S Viennot, A Aubourg, A-L Pelletier, G Bouguen, V Abitbol, C Gagniere, Y Bouhnik
BACKGROUND: We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. AIMS: To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. METHODS: Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with vedolizumab induction therapy...
June 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28589323/elderly-psoriatic-arthritis-patients-on-tnf-%C3%AE-blockers-results-of-an-italian-multicenter-study-on-minimal-disease-activity-and-drug-discontinuation-rate
#19
Luisa Costa, Ennio Lubrano, Roberta Ramonda, Maria Sole Chimenti, Maristella Vezzù, Fabio M Perrotta, Antonio Del Puente, Rosario Peluso, Paolo Bottiglieri, Mariagrazia Lorenzin, Flavia Sunzini, Md Abud Darda, Ugo Fiocco, Roberto Perricone, Leonardo Punzi, Raffaele Scarpa, Francesco Caso
Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy and safety of TNF-α blockers in the elderly with PsA are lacking. The aim of this study was to evaluate the effectiveness, through the achievement of minimal disease activity (MDA), drug discontinuation rate, and safety in elderly patients with PsA on TNF-α blockers. A multicenter, observational study was carried out in four Italian centers. The assessment of disease activity and safety were performed at the start of anti-TNF-α (T0), at 6 months (T6) and at 12 months (T12)...
August 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28579754/paradoxical-sapho-syndrome-observed-during-anti-tnf%C3%AE-therapy-for-crohn-s-disease
#20
Hitoshi Amano, Reikei Matsuda, Tomohiko Shibata, Daisuke Takahashi, Shinichiro Suzuki
Currently, anti-TNFα antibodies are used to treat Crohn's disease. We report on a 45-year-old Japanese female with Crohn's disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Cutaneous and articular involvement were exacerbating the condition, so adalimumab was discontinued and the patient was put on low-dose methotrexate to control her symptoms...
2017: Biologics: Targets & Therapy
keyword
keyword
61555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"